<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0">
  <channel>
    <title>Featured Headlines Feed for ONCY</title>
    <link />
    <description>Headlines for Oncolytics Biotech, Inc. (USA)</description>
    <docs>http://www.rssboard.org/rss-specification</docs>
    <generator>Argotic Syndication Framework 2008.0.2.0, http://www.codeplex.com/Argotic</generator>
    <item>
      <title>Promising Data on ONCY's Reolysin - Analyst Blog</title>
      <link>http://www.fool.com/news/xt/zacks/www.zacks.com/stock/news/100186/promising-data-on-oncys-reolysin.aspx</link>
      <author>Zacks</author>
      <pubDate>Fri, 24 May 2013 21:40:01 GMT</pubDate>
    </item>
    <item>
      <title>A New Cancer-Killing Virus</title>
      <link>http://www.fool.com/news/xt/aol-daily-finance/www.dailyfinance.com/2013/05/22/a-new-cancer-killing-virus/.aspx</link>
      <author>DailyFinance</author>
      <pubDate>Wed, 22 May 2013 18:45:00 GMT</pubDate>
    </item>
    <item>
      <title>Can Financial Innovation Unlock a Cure for Cancer?</title>
      <link>http://www.fool.com/news/xt/aol-daily-finance/www.dailyfinance.com/2013/05/22/can-financial-innovation-unlock-a-cure-for-cancer/.aspx</link>
      <author>DailyFinance</author>
      <pubDate>Wed, 22 May 2013 18:32:00 GMT</pubDate>
    </item>
    <item>
      <title>U.S. HOT STOCK FUTURES: HOT STOCKS TO WATCH</title>
      <link>http://www.fool.com/news/xt/smartmoney/www.smartmoney.com/news/on/.aspx?story=on-20130522-000419&amp;cid=1244</link>
      <author>Smart Money</author>
      <pubDate>Wed, 22 May 2013 09:00:59 GMT</pubDate>
    </item>
    <item>
      <title>Oncolytics Announces First Stage of Metastatic Melanoma Phase 2 Trial Meets Primary Endpoint</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/news/13/05/3610710/oncolytics-announces-first-stage-of-metastatic-melanoma-phase-2-trial-meets-prima.aspx</link>
      <author>Benzinga</author>
      <pubDate>Wed, 22 May 2013 06:41:03 GMT</pubDate>
    </item>
    <item>
      <title>Oncolytics Biotech's CEO Presents at 2013 Annual Meeting of Shareholders Conference (Transcript)</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1426761-oncolytics-biotech-s-ceo-presents-at-2013-annual-meeting-of-shareholders-conference-transcript.aspx</link>
      <author>Seeking Alpha</author>
      <pubDate>Sat, 11 May 2013 01:33:05 GMT</pubDate>
    </item>
    <item>
      <title>Oncolytics: A Failing Biopharma, Or An Opportune Buy?</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1325941-oncolytics-a-failing-biopharma-or-an-opportune-buy.aspx</link>
      <author>Seeking Alpha</author>
      <pubDate>Mon, 08 Apr 2013 03:15:25 GMT</pubDate>
    </item>
    <item>
      <title>Oncolytics Phase 2 Study of REOLYSIN Meets Primary Endpoint in Squamous Cell Lung Cancer</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/news/13/03/3453808/oncolytics-phase-2-study-of-reolysin-meets-primary-endpoint-in-squamous-cell-lung.aspx</link>
      <author>Benzinga</author>
      <pubDate>Thu, 28 Mar 2013 06:32:56 GMT</pubDate>
    </item>
    <item>
      <title>3 Potential Game-Changing Cancer Drugs</title>
      <link>http://www.fool.com/news/xt/aol-daily-finance/www.dailyfinance.com/2013/03/09/3-potential-game-changing-cancer-treatments/.aspx</link>
      <author>DailyFinance</author>
      <pubDate>Sat, 09 Mar 2013 12:00:00 GMT</pubDate>
    </item>
    <item>
      <title>A Peek Into The Market Before The Trading Starts</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/news/13/03/3389644/a-peek-into-the-market-before-the-trading-starts.aspx</link>
      <author>Benzinga</author>
      <pubDate>Tue, 05 Mar 2013 07:11:12 GMT</pubDate>
    </item>
    <item>
      <title>Oncolytics Completes Enrollment for US Phase 2 Study of REOLYSIN in Non-Small Cell Lung Cancer</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/news/13/03/3389484/oncolytics-completes-enrollment-for-us-phase-2-study-of-reolysin-in-non-small-cel.aspx</link>
      <author>Benzinga</author>
      <pubDate>Tue, 05 Mar 2013 06:45:37 GMT</pubDate>
    </item>
    <item>
      <title>Oncolytics' Rough Ride</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1246211-oncolytics-rough-ride.aspx</link>
      <author>Seeking Alpha</author>
      <pubDate>Tue, 05 Mar 2013 01:15:37 GMT</pubDate>
    </item>
    <item>
      <title>Benzinga's Top Initiations</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/analyst-ratings/initiation/13/03/3385355/benzingas-top-initiations.aspx</link>
      <author>Benzinga</author>
      <pubDate>Mon, 04 Mar 2013 07:26:59 GMT</pubDate>
    </item>
    <item>
      <title>Biotech Stock Mailbag: Ziopharm, Oncolytics, Sarepta</title>
      <link>http://www.fool.com/news/xt/thestreet/www.thestreet.com/story/11855905/1/biotech-stock-mailbag-ziopharm-oncolytics-sarepta.html.aspx?puc=aol&amp;cm_ven=aol</link>
      <author>TheStreet</author>
      <pubDate>Fri, 01 Mar 2013 06:00:00 GMT</pubDate>
    </item>
    <item>
      <title>Oncolytics Closes Offering of 8M Shares at $4/Share for Gross Proceeds of $32M</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/news/13/02/3363516/oncolytics-closes-offering-of-8m-shares-at-4share-for-gross-proceeds-of-32m.aspx</link>
      <author>Benzinga</author>
      <pubDate>Mon, 25 Feb 2013 11:54:33 GMT</pubDate>
    </item>
    <item>
      <title>3 Horrendous Health-Care Stocks This Week</title>
      <link>http://www.fool.com/news/xt/aol-daily-finance/www.dailyfinance.com/2013/02/22/3-horrendous-health-care-stocks-this-week-17/.aspx</link>
      <author>DailyFinance</author>
      <pubDate>Fri, 22 Feb 2013 16:29:00 GMT</pubDate>
    </item>
    <item>
      <title>These 3 Stocks Aren't as Wobbly as They Appear</title>
      <link>http://www.fool.com/news/xt/aol-daily-finance/www.dailyfinance.com/2013/02/21/these-3-stocks-arent-as-wobbly-as-they-appear/.aspx</link>
      <author>DailyFinance</author>
      <pubDate>Thu, 21 Feb 2013 15:09:00 GMT</pubDate>
    </item>
    <item>
      <title>U.S. HOT STOCK FUTURES: HOT STOCKS TO WATCH</title>
      <link>http://www.fool.com/news/xt/smartmoney/www.smartmoney.com/news/on/.aspx?story=on-20130220-000355&amp;cid=1244</link>
      <author>Smart Money</author>
      <pubDate>Wed, 20 Feb 2013 09:01:59 GMT</pubDate>
    </item>
    <item>
      <title>U.S. HOT STOCK FUTURES: HOT STOCKS TO WATCH</title>
      <link>http://www.fool.com/news/xt/smartmoney/www.smartmoney.com/news/on/.aspx?story=on-20130220-000296&amp;cid=1244</link>
      <author>Smart Money</author>
      <pubDate>Wed, 20 Feb 2013 06:48:00 GMT</pubDate>
    </item>
    <item>
      <title>Oncolytics Biotech Poised To Climb</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1176151-oncolytics-biotech-poised-to-climb.aspx</link>
      <author>Seeking Alpha</author>
      <pubDate>Tue, 12 Feb 2013 16:23:17 GMT</pubDate>
    </item>
  </channel>
</rss>
